Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160

The development of a vaccine to provide protective immunity to human immunodeficiency virus type 1 (HIV-1), the virus causing AIDS, would be the most practical method to control its spread. Subunit vaccines consisting of virus envelope glycoproteins, produced by recombinant DNA technology, are effec...

Full description

Saved in:

Bibliographic Details
Published in:	Nature (London) Vol. 345; no. 6276; pp. 622 - 625
Main Authors:	Berman, Phillip W, Gregory, Timothy J, Riddle, Lavon, Nakamura, Gerald R, Champe, Mark A, Porter, James P, Wurm, Florain M, Hershberg, Robert D, Cobb, E. Kathy, Eichberg, Jorg W
Format:	Journal Article
Language:	English
Published:	London Nature Publishing 14-06-1990 Nature Publishing Group
Subjects:	Acquired immune deficiency syndrome Acquired Immunodeficiency Syndrome - prevention & control AIDS AIDS/HIV Animals Antigens, CD - metabolism Biological and medical sciences CD4 Antigens - metabolism Chimpanzees Deoxyribonucleic acid DNA Fundamental and applied biological sciences. Psychology Gene Products, env - immunology Glycoprotein gp120 Glycoprotein gp160 Glycoproteins HIV HIV Antibodies - analysis HIV Antigens - immunology HIV Envelope Protein gp120 - immunology HIV Envelope Protein gp120 - metabolism HIV Envelope Protein gp160 HIV-1 - immunology Homology Human immunodeficiency virus human immunodeficiency virus 1 Immunity Immunization Immunoglobulins Infections Medical research Microbiology Monkeys & apes Pan troglodytes Protein Precursors - immunology Proteins Public health Recombinant DNA Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies Vaccines, Synthetic Viral Vaccines Virology Viruses Immunoprotection Immunization Immune response HIV-1 virus Vaccination Monkey Retroviridae Glycoproteins Virus Vertebrata Mammalia Primates Lentivirinae Human immunodeficiency virus Virus envelope Humoral immunity
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The development of a vaccine to provide protective immunity to human immunodeficiency virus type 1 (HIV-1), the virus causing AIDS, would be the most practical method to control its spread. Subunit vaccines consisting of virus envelope glycoproteins, produced by recombinant DNA technology, are effective in preventing viral infections. We have now used this approach in the development of a candidate AIDS vaccine. Chimpanzees were immunized with recombinant forms of the HIV-1 glycoproteins gp120 and gp160 produced in Chinese hamster ovary cells, and then challenged with HIV-1. The control and the two animals immunized with the gp160 variant became infected within 7 weeks of challenge. The two animals immunized with the gp120 variant have shown no signs of infection after more than 6 months. These studies demonstrate that recombinant gp120, formulated in an adjuvant approved for human use, can elicit protective immunity against a homologous strain of HIV-1.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2
ISSN:	0028-0836 1476-4687
DOI:	10.1038/345622a0